



US006239118B1

(12) **United States Patent**  
Schatz et al.

(10) Patent No.: **US 6,239,118 B1**  
(45) Date of Patent: **May 29, 2001**

(54) **METHOD FOR PREVENTING RESTENOSIS USING A SUBSTITUTED ADENINE DERIVATIVE**

(76) Inventors: **Richard A. Schatz**, P.O. Box 8517, Rancho Santa Fe, CA (US) 92067; **Alan Saven**, 13016 Walking Path Pl., San Diego, CA (US) 92130

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/412,418**

(22) Filed: **Oct. 5, 1999**

(51) Int. Cl.<sup>7</sup> ..... **A61K 31/70**

(52) U.S. Cl. .... **514/45; 514/46**

(58) Field of Search ..... **514/46, 45**

(56) **References Cited**

#### U.S. PATENT DOCUMENTS

5,106,837 4/1992 Carson et al. .  
5,424,296 6/1995 Saven et al. .  
5,510,336 4/1996 Saven et al. .

#### OTHER PUBLICATIONS

Libby et al, *Nouv Rev Fr Hematol*, 34 Suppl. S47-53, 1992.\*

Faxon, David P., M.D., Chronic Inflammation, *Clinical Trials and Remodeling*; pp. 136-138; University of Southern California School of Medicine, Los Angeles, CA; Restenosis Summit VIII, 1996.

Gerrity, Ross G., PhD. *The Role of the Monocyte in Atherogenesis*, pp. 181 and 191; Research Division, The Cleveland Clinic Foundation, Cleveland, Ohio, Nov. 1, 1980.

Leibovich, S. J. PhD. et al., A Macrophage-Dependent Factor That Stimulates the Proliferation of Fibroblasts in Vitro; *American Journal of Pathology*; pp. 501,508, and 511; Department of Pathology, University of Washington School of Medicine, Seattle, Washington, Apr. 23, 1976.

Ross, Russell, PhD., Mechanism of Disease Atherosclerosis—An Inflammatory Disease, *The New England Journal of Medicine* vol. 340, No. 2, pp. 115-126; Department of Pathology, University of Washington School of Medicine, Seattle, Washington; Jan. 14, 1999.

Ross, Russell, PhD. Medical Progress; The Pathogenesis of Atherosclerosis—An Update; *The New England Journal of Medicine* vol. 314, No. 8, pp. 488, 493, 494; Department of Pathology, University of Washington School of Medicine, Seattle, Washington; Feb. 20, 1986.

Saven, Alan, M.D., et al.; Brief Communications, 2-Chlorodeoxyadenosine-induced Complete Remissions in Langerhans-Cell Histiocytosis, pp. 430-432; Reprinted from *Annals of Internal Medicine*, vol. 121, No. 6, Sep. 15, 1994.

Schwartz, Stephen M., et al; Remodeling: How Vessels Narrow, *Clinical Trials and Remodeling*; pp. 128-131; University of Washington, Seattle, WA; Massachusetts General Hospital, Boston, MA; and ZymoGenetics, Inc., Seattle WA. 1996.

Waltenberger, Johannes, M.D., Current Perspectives, Modulation of Growth Factor Action, Implications for the Treatment of Cardiovascular Diseases; *Circulation*, pp. 4083-4094; vol. 96, No. 11, Department of Internal Medicine II (Cardiology); Ulm University Medical Center, Ulm, Germany; Dec. 2, 1997.

Copy of Brochure for Leustatin® (cladribine) Injection; Ortho Biotech, Raritan, New Jersey, Dec. 1996.

\* cited by examiner

Primary Examiner—Rebecca Cook

(74) Attorney, Agent, or Firm—Nydegger & Associates

(57) **ABSTRACT**

The present invention discloses a method for the prevention of atherosclerosis, its genesis, progression and restenosis in human patients undergoing treatments for arterial lesions such as PTA or atherectomy, and which may be accompanied by stent implantation. Further, the treatment method disclosed has applicability in all stages of atherosclerosis in which monocytes play a role. The compound utilized in the present method as the active agent is a 2-halo-2'-deoxyadenosine such as 2-chloro-deoxyadenosine (2-CdA). The treatment method of the present invention includes the administration of 14 doses of 2-CdA in the amount of 0.12 mg/kg. One dose is given intravenously before the coronary intervention, another is given intravenously after the intervention and the remaining twelve doses are given subcutaneously at weekly intervals over a subsequent three month period.

**15 Claims, No Drawings**